Effect of pretreatment clinical factors on overall survival in glioblastoma multiforme: a Surveillance Epidemiology and End Results (SEER) population analysis

Table 5 Univariate median survival estimates (months) and hazard ratios of patients with GBM by racial groups, diagnosis year groups, and age groups

	Median Survival		Hazard Ratio
	n	95% CI	Estimate	95% CI	P-value**
Racial Groups
White*	31,820	6 ± 0.11	reference
Black	1,526	6 ± 0.61	0.95	0.89 to 1.00	0.066
Asian/Pacific Islander	1,177	8 ± 0.67	0.83	0.78 to 0.89	<0.001
American Indian/ Alaskan Native	87	6 ± 2.03	0.86	0.68 to 1.10	0.237
Unknown	39	9 ± 6.10	0.59	0.37 to 0.88	0.009
Other	15	6 ± 19.91	0.75	0.35 to 1.43	0.467
Diagnosis Year Groups
1973 to 1979*	2,836	5 ± 0.35	reference
1980 to 1989	4,528	6 ± 0.28	0.93	0.88 to 0.98	0.005
1990 to 1999	8,265	6 ± 0.20	0.93	0.89 to 0.98	0.005
2000 to 2008	19,035	7 ± 0.18	0.78	0.74 to 0.81	<0.001
Radiation Treatment Groups
Yes*	23,386	9 ± 0.13	reference
No	10,174	2 ± 0.06	3.45	3.33 to 3.45	<0.001
Unknown	1,104	3 ± 0.26	2.50	2.33 to 2.70	<0.001
Extent of Surgery Groups
Surgical Resection*	23,802	9 ± 0.14	reference
No Cancer Directed Resection	8,611	3 ± 0.09	2.38	2.33 to 2.44	<0.001
Unknown	2,251	3 ± 0.18	0.96	0.93 to 1.00	0.126
Age (Continuous Variable)
Age	34,664		1.037	1.036 to 1.038	<0.001
Age Groups
<50*	5,732	14 ± 0.37	reference
>=50	28,932	5 ± 0.10	2.22	2.17 to 2.33	<0.001
Ten-Year Age-Bands (<50 only)
20 to 29*	604	20 ± 2.37	reference
30 to 39	1,342	16 ± 1.05	1.23	1.10 to 1.39	<0.001
40 to 49	3,786	12 ± 0.39	1.85	1.67 to 2.04	<0.001

ISSN: 1477-7819